Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.46 |
| ▸ | FABP7 | O15540 | 2/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.43 |
| ▸ | ITGAV | P06756 | 1/20 | 0.43 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.43 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 3/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | PREP | P48147 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL119867 | 1.00 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2RAB9AFABP5FABP7 | |
| SCHEMBL29402209 | 1.00 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2RAB9AFABP5FABP7 | |
| SCHEMBL29383097 | 1.00 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2RAB9AFABP5FABP7 | |
| SCHEMBL119365 | 1.00 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2RAB9AFABP5FABP7 | |
| SCHEMBL30510359 | 1.00 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2RAB9AFABP5FABP7 | |
| SCHEMBL29447672 | 1.00 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2RAB9AFABP5FABP7 | |
| SCHEMBL17359219 | 0.99 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2RAB9AFABP5FABP7 | |
| SCHEMBL30792899 | 0.99 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2RAB9AFABP5FABP7 | |
| SCHEMBL27028706 | 0.99 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2RAB9AFABP5FABP7 | |
| SCHEMBL119560 | 0.96 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2RAB9AFABP5FABP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117143179-B | Synthesis method of thrombin chromogenic substrate S-2238 | 安徽峆一药业股份有限公司 | 2024-07-12 | — | — | CN | claimed |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-29 | — | — | US | disclosed |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-12-05 | — | — | US | disclosed |
| CN-117143179-B | Synthesis method of thrombin chromogenic substrate S-2238 | 安徽峆一药业股份有限公司 | 2024-07-12 | — | — | CN | disclosed |
| US-20240218021-A1 | CYCLIN INHIBITORS | CIRCLE PHARMA, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-09 | — | — | US | disclosed |
| EP-4316503-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-07 | — | — | EP | disclosed |
| CN-117143179-A | Synthesis method of thrombin chromogenic substrate S-2238 | 安徽峆一药业股份有限公司 | 2023-12-01 | — | — | CN | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| EP-3515880-B1 | METHODS AND COMPOSITIONS FOR SYNTHESIS OF ENCODED LIBRARIES | HITGEN INC (CN) | 2023-05-10 | — | — | EP | disclosed |
| WO-1999003832-A1 | PIPERIDINE OLIGOMERS AND COMBINATORIAL LIBRARIES THEREOF | PHYTERA SYMBION APS (DK) | 1999-01-28 | — | — | WO | disclosed |
| EP-0888303-A1 | SYNTHETIC DERIVATIVES OF RAPAMYCIN AS MULTIMERIZING AGENTS FOR CHIMERIC PROTEINS WITH IMMUNOPHILIN-DERIVED DOMAINS | ARIAD GENE THERAPEUTICS, INC. (US) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997031898-A1 | SYNTHETIC DERIVATIVES OF RAPAMYCIN AS MULTIMERIZING AGENTS FOR CHIMERIC PROTEINS WITH IMMUNOPHILIN-DERIVED DOMAINS | ARIAD GENE THERAPEUTICS, INC. (US) | 1997-09-04 | — | — | WO | disclosed |
| EP-0502926-B1 | ANTI-THROMBOTIC PEPTIDES AND PSEUDOPEPTIDES | RHONE POULENC RORER INT (US) | 1996-03-13 | — | — | EP | disclosed |
| US-5328900-A | Anti-thrombotic peptide and pseudopeptide derivatives | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1994-07-12 | — | — | US | disclosed |
| EP-0502926-A1 | ANTI-THROMBOTIC PEPTIDES AND PSEUDOPEPTIDES. | RHONE POULENC RORER INT (US) | 1992-09-16 | — | — | EP | disclosed |
| EP-0502926-A4 | ANTI-THROMBOTIC PEPTIDES AND PSEUDOPEPTIDES. | RHONE POULENC RORER INTERNAT H (US) | 1992-07-13 | — | — | EP | disclosed |
| US-5064814-A | Anti-thrombotic peptide and pseudopeptide derivatives | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1991-11-12 | — | — | US | disclosed |
| US-5053392-A | Anticoagulants | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1991-10-01 | — | — | US | disclosed |
| WO-1991007976-A1 | ANTI-THROMBOTIC PEPTIDES AND PSEUDOPEPTIDES | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1991-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | ALDH1A1 4838/4885SMN1; SMN2 4201/4885RAB9A 65/4885 |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | ALDH1A1 4838/4885SMN1; SMN2 4201/4885RAB9A 65/4885 |
| US-20240218021-A1 | CYCLIN INHIBITORS | CCNI, CCNC, CDK2 | ALDH1A1 2597/4885SMN1; SMN2 2812/4885RAB9A 3397/4885 |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | VIP, IAPP, KRAS | ALDH1A1 4861/4885SMN1; SMN2 4745/4885RAB9A 98/4885 |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | KRAS, NRAS, HRAS | ALDH1A1 4838/4885SMN1; SMN2 4201/4885RAB9A 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.